Our Approach in the Preparation for Thymectomy in Myasthenia Gravis

  • Jose M. Ponseti
  • Eloy Espín
  • Jose M. Fort
  • Carlos Vicens
  • Manuel Armengol
Chapter

Abstract

Thymectomy, first performed by Sauerbruch in 1912, became a major treatment in myasthenia gravis although no prospective study of its value has ever been made (1–5). Since the first thymectomies, postoperative myasthenic crisis, has been one of the most important and feared postoperative complications, with a mortality rate ranging from 15%–33,3% in the 1950s to a current 3% (6–9).

Keywords

Intensive Care Unit Stay Myasthenic Crisis Bulbar Symptom Anticholinesterase Agent Impaired Respiratory Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Perlo VP, Poskenzer DD, Schwab RS, Viets H, Osserman KO, Genkins G. Myasthenia gravis: Evaluation of treatment in 1,355 patients. Neurology 1966; 16:431–442.PubMedCrossRefGoogle Scholar
  2. 2.
    Buckingham JM, Howard FM Jr, Bernatz PE. The value of thymectomy in myasthenia gravis: a computerassisted matched study. Ann Surg 1976; 184:453–458.PubMedCrossRefGoogle Scholar
  3. 3.
    Olanow CW, Wechsler AS, Sirotkiin-Roses M. Thymectomy as primary therapy in myasthenia gravis. Ann NY Acad Sci. 1987; 505:595–606.PubMedCrossRefGoogle Scholar
  4. 4.
    Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP, Pozner J, Aufses AH: Efects of thymectomy in Myasthenia Gravis. Ann Surg. 1987; 206: 79–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Otto TJ, Strugalska H. Surgical treatment for myasthenia gravis. Thorax 1987; 42:199–204.PubMedCrossRefGoogle Scholar
  6. 6.
    Galofre M, Ponseti JM. Timectomia en la miastenia gravis. Barcelona Quirurgica 1971; 15:449–453.Google Scholar
  7. 7.
    Osserman KE. Myasthenia Gravis. Grune & Stratton. NY. 1958; 165-183.Google Scholar
  8. 8.
    Viets HR. Myasthenia Gravis. The second international symposium proceedings. Charles C Thomas Publisher, Bannerstone House, Springfiie, Illinois, USA. 1961; 637-652.Google Scholar
  9. 9.
    Molnár J, Szobor A. Myasthenia gravis: effect of thymectomy in 425 patients. A 15-year experience. Eur J Cardio-thorac Surg 1990; 4:8–14.CrossRefGoogle Scholar
  10. 10.
    Walker MB: Treatment of myasthenia gravis with physostigmine. Lancet 1934; 1: 1200–1201.CrossRefGoogle Scholar
  11. 11.
    Oosterhuis HJ. Observations of the natural history of myasthenia gravis an the efect of thymectomy. Ann NY Acad Sci 1981; 377: 678–690.PubMedCrossRefGoogle Scholar
  12. 12.
    Martens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969; 2:321–339.CrossRefGoogle Scholar
  13. 13.
    Ponseti JM, Galofre M. Prespectivas actuales en el tratamiento de la miastenia gravis. Med Clin (Barc) 1972; 58:308–313.Google Scholar
  14. 14.
    Mertens HG, Hertel G, Renther P, et al: Effect of immunosuppressive drugs(azathioprine). Ann NY Acad Sci 1981; 377: 691–699.PubMedCrossRefGoogle Scholar
  15. 15.
    Patrick J, Lindstrom J: Antiimmune response to acetylcholine receptor. Science 1973; 180:871–872.PubMedCrossRefGoogle Scholar
  16. 16.
    Dau PC, Lindstrom CK, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasma pheresis and immunosuppessive drog therapy in myasthenia gravis. N Engl J Med 1977; 1134-1140.Google Scholar
  17. 17.
    Dau PC: Plasmapheresis and the Immunobiologi of Myasthenia Gravis. Houghton Mifflin, Boston 1979Google Scholar
  18. 18.
    Ponseti JM. Miastenia gravis y timoma. Rev Neurol. 1975; 3:279–287.Google Scholar
  19. 19.
    Ponseti JM, Plasmaferesis en el tratamiento de la miastenia gravis. Med Clin (Barc) 1983; 80: 121–122.Google Scholar
  20. 20.
    Gajdos P, Outin H, Elkharrat D, Brunei D, Rohan-Chabot P, Raphael JC, Goulon M, Goulon-Goeau C, Morel E: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 406-407.Google Scholar
  21. 21.
    Fateh-Moghadam A, Wick M, Besinger U, Geursen RG: High-dose Intravenous gammaglobulin for myasthenia gravis: Lancet 1984; 848-849.Google Scholar
  22. 22.
    Ippoliti G, Cosi V, Piccolo G, Lombardi G, Mantegaz R. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 2: 809.CrossRefGoogle Scholar
  23. 23.
    Devathasan G, Kneh YK, Chng PN. High-dose intravenous gammaglobulin for myasthenia gravis Lancet 1984;2:809–810.Google Scholar
  24. 24.
    Arsura EL, Bick A, Brunner G, Namba T, Grob D: High-dose intravenous immunoglobulin in the managment of myasthenia gravis: Arch Intern Med 1986; 146: 1365–1368.PubMedCrossRefGoogle Scholar
  25. 25.
    Bonaventura I, Ponseti J, Espanol T, Matias-Guiu J, Codina-Puiggros A. High-dose intravenous gammaglobulin therapy for myasthenia gravis. J Neurol 1987; 234: 363.CrossRefGoogle Scholar
  26. 26.
    Szobor A. Crises in Myasthenia Gravis. Hafner Publishing Company, NY. 1970; 39-42.Google Scholar
  27. 27.
    Grob D, Brunner NG, Namba T: The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981; 377: 652–669.PubMedCrossRefGoogle Scholar
  28. 28.
    Rodriguez M, Gomez MR, Howard FM, Taylor WF: Myasthenia gravis in children: long-term fallow-up. Ann Neurol 1983; 13: 504–510.PubMedCrossRefGoogle Scholar
  29. 29.
    Pradas J, Illa I, Tratamiento de la miastenia gravis: Sant Pau 1984; 5: 24–39.Google Scholar
  30. 30.
    Cooper JD, Al-Jilaihawa AN, Pearson FG, Humphrey JG, Humphrey HE. An improved Technique to facilitate transcervical thymectomy for myasthenia gravis. Ann Thorac Surg. 1988; 45:242–247.PubMedCrossRefGoogle Scholar
  31. 31.
    Mulder DG, Graves M, Herrmann C. Thymectomy for Myasthenia Gravis: Recent Observations and Comparisons With Past Experience. Ann Thorac Surg 1989; 48:551–555.PubMedCrossRefGoogle Scholar
  32. 32.
    Ponseti JM. Contribucion al estudio de la miastenia gravis. Valor de la espirometria como indice de recuperacion. Resumen de Tesis Doctoral. Universidad Autónoma de Barcelona, 1977Google Scholar
  33. 33.
    Jaretzki III J, Penn AS, Younger DS, Wolff M Olarte MR, Lovelace RE, Rowland LP, “Maximal” thymectomy for myasthenia gravis. J Thorac Cardiovasc Surg 1988; 95: 747–757.PubMedGoogle Scholar
  34. 34.
    Kornfeld P, Merav A, Fox S, Maier K. Haw reliable are imaging procedures in detectin residual thymus after previus thymectomy. Ann NY Acd Sci 1993; 681:575–576.CrossRefGoogle Scholar
  35. 35.
    Fischer JE, Grinvalski HT, Nussbaum MS, Sayers HJ, Cole RE, Samaha FJ. Aggressive surgical approach for drug-free remission from myasthenia gravis. Ann Surg 1987;205:496–503.PubMedCrossRefGoogle Scholar
  36. 36.
    Hankins JR, Maye RF, Satterfielt JR, Turney SZ, Attar S, Sequeira AJ, Thompson SW, McLaughlin JS. Thymectomy for myasthenia gravis: 14-year experience. Ann Surg 1985; 201:18–25.CrossRefGoogle Scholar
  37. 37.
    Olanow CW, Wechsler AS, Roses AD. A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg 1982; 196:113–121.PubMedCrossRefGoogle Scholar
  38. 38.
    Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP, Pozner J, Aufses AH. Effects of thymectomy in myasthenia gravis. Ann Surg 1987; 201:79–88.CrossRefGoogle Scholar
  39. 39.
    Kirschner PA. Myasthenia gravis and other parathymyc syndromes. Chest Sur Clin N A. 1992;2. 1. 183-201.Google Scholar
  40. 40.
    Simpson JA: Myasthenia gravis: A new hypothesis. Scott Med J. 1960; 5: 419–436.Google Scholar
  41. 41.
    Nastuk WL, Plescia OJ, Osserman KE: Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 1960; 105: 177–184.PubMedCrossRefGoogle Scholar
  42. 42.
    Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymectomy in myesthenia gravis: Resutls of 662 cases operated upon in 15 years. Eur J Cardio-thorac Surg. 1989; 3:504–511.CrossRefGoogle Scholar
  43. 43.
    Sato T, Nishimiya J, Arai K, Anno M, Yamawaki N, Kuroda T, Inagaki K. Selective removal of anti-acetylcholine receptor antibodies in sera patients with myasthenia gravis in vitro with a new immunosorbent. In: Oda T, ed. Therapeutic Plasmapheresis (III). Stuttgart-New York: Schattauer, 1983; 565-568Google Scholar
  44. 44.
    Heininger K, Gaczkowski A, Hartung HP Toyka KV, Borberg H. Plasma separation and imunoadsorption in myasthenia gravis. Therapeutic Plasmapheresis (V) Ed. Shattauer. 1985; 3-10.Google Scholar
  45. 45.
    Passalacqua S, Splendiani G, Sturniolo A, Costanzi S, Barbera G, Bartoccioni E, Evoli A, Scoppetta C, Adorno D, Di Guilio S, Casciani CU. Immunosorbent treatment in myasthenia gravis. Apheresis. Alan R. Lisslnc. 1990; 285-288.Google Scholar
  46. 46.
    Kawanami S, Mori S, Uchida T, Nagasawa H, Shirotani T, Naito S, Shibuya N. Therapeutic Plasmapheresis (IX) ICAOT Press. Cleveland. 1991; 318:167–171.Google Scholar
  47. 47.
    Avanzi G, Marconi G. Semiselective Immunoadsorption of Anti-AChR abs on TRyptophan Column in Myasthenia Gravis. Clinical Experience in 32 Patients. Transfus. Sci. 1993; 14:17–21.Google Scholar
  48. 48.
    Strieker RB, Kwiatkowska BJ, Habis JA, MacLeod DE, Kiprov DD. Response to plasmapheresis following failure of intravenous gammaglobulin in patients with Myasthenia Gravis and Guillain-Barre Syndrome. J Clin Apheresis 1993; 8: 733.Google Scholar
  49. 49.
    Ferrero B, Durelli I, Cavallo R, Dutto A, Aimo G, Pecchio F, Bergamasco B. Therapies for exacerbation of Myasthenia Gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann NY Acd Sci 1993; 681:563–566.CrossRefGoogle Scholar
  50. 50.
    Arsura EL, Bick A, Bruner NG, Grob B. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988; 295:438–443.PubMedCrossRefGoogle Scholar
  51. 51.
    Fort JM, Ponseti JM. Altas dosis de globulina gamma intravenosa en el tratamiento de la miastenia gravis. Med Clin (Barc) 1988; 91:325–328.Google Scholar
  52. 52.
    Zweiman B. Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis. Clin Immunol Immunopathol. 1989; 53: 83–91.CrossRefGoogle Scholar
  53. 52.
    Ponseti JM. Miastenia Gravis. Manual Terapéutico. Springer-Verlag Ibérica. Barcelona. 1995; 139-145.Google Scholar
  54. 54.
    Drachman DB. Myasthenia Gravis. N Engl J Med 1994; 330:1797–1810.PubMedCrossRefGoogle Scholar
  55. 55.
    Edan G, Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(Supplement):55-56.Google Scholar
  56. 56.
    Strieker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic Crisis: Response to Plasmapheresis following failure of intravenous γ-Globulin. Arch Neurol 1993; 50:837–840.CrossRefGoogle Scholar
  57. 57.
    Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis.In Myasthenia Gravis and Myasthenic Syndromes. Edited by Sanders DB. Neurologic Clinics 1994; 12:343-368Google Scholar
  58. 58.
    Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789–790.PubMedCrossRefGoogle Scholar
  59. 59.
    Lam L, Whitsett CF, McNicoll JM, Hodge TW, Hooper J: Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678.PubMedCrossRefGoogle Scholar
  60. 60.
    Ahlberg R, Yi Q, Pirskanen R, Martell G, Swerup C, Rieber P, Riethmuller G, Holm G, Lefvert AK. Clinical improvement of Myasthenia Gravis by treatment with a chimeric ant-CD4 monoclonal antibody. Ann NY Acd Scti 1993; 681:552–555.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Jose M. Ponseti
    • 1
  • Eloy Espín
    • 1
  • Jose M. Fort
    • 1
  • Carlos Vicens
    • 1
  • Manuel Armengol
    • 1
  1. 1.Myasthenia Gravis Unit, Department of Surgery, Hospital General Vall d’HebronUniversidad Autonoma de BarcelonaBarcelonaSpain

Personalised recommendations